GNX201-ADC | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

5,005 results for “GNX201-ADC”

Trials

View all 2881 →

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

150 participants · First posted Aug 28, 2025

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

160 participants · First posted Oct 18, 2024

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

120 participants · First posted Mar 25, 2024

Drugs

View all 749 →

GNX201

masked ADC

PSMA-ADC-1301

Organizations

View all 68 →

ADC Therapeutics

Switzerland

ADC Therapeutics America, Inc.

United States

Lophora ApS

Denmark

News

View all 1307 →

GlycoNex Partners with Nippon Kayaku to Develop Tumor-Activated ADC GNX201 for Solid Tumors

GlycoNex Partners with Sterling for GNX102-ADC Clinical Trial Manufacturing

GlycoNex Partners with Sterling for GNX102-ADC Clinical Trial Production

Page 1 of 501